The effects of neoadjuvant sintilimab versus pembrolizumab combined with chemotherapy on resectable non-small cell lung cancer: a multicenter propensity score-matched study

Yichen Sun, Zhiyuan Gao, Zhilin Luo, Liping Tong, Yong Zhang, Xiaoping Dong, Junying Wang, Wenjing Li, Ziyi Li, Weiru Qiao, Xian Chen, Hongtao Duan, Xiaolong Yan · 2025

Read The effects of neoadjuvant sintilimab versus pembrolizumab combined with chemotherapy on resectable non-small cell lung cancer: a multicenter propensity score-matched study by Yichen Sun, Zhiyuan Gao, Zhilin Luo, Liping Tong, Yong Zhang, Xiaoping Dong, Junying Wang, Wenjing Li, Ziyi Li, Weiru Qiao, Xian Chen, Hongtao Duan, Xiaolong Yan (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12775710.txt.

Description

Yichen Sun leads a team of thirteen in a 2025 study that pits two immune drugs against each other before lung surgery. Both drugs free the immune system to attack cancer, and each pairs with chemo to shrink a lung tumor before the cut. Which one does better had not been faced off.

Records from two hospitals covered 366 patients from 2018 to 2024, some on each drug. Matching on patient traits leveled the field. The team then compared shrink rates, full tumor death in the cut tissue, and how the surgery went. Early answers guide a choice that clinics now make blind.

Catalog record

CREATORYichen Sun, Zhiyuan Gao, Zhilin Luo, Liping Tong, Yong Zhang, Xiaoping Dong, Junying Wang, Wenjing Li, Ziyi Li, Weiru Qiao, Xian Chen, Hongtao Duan, Xiaolong Yan
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE31 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12775710

Browse the full library · About the Tower of Babel